Christopher Barbieri
About Christopher Barbieri
Christopher Barbieri is the Associate Director at Bristol Myers Squibb in New Jersey, United States, with extensive experience in biochemistry and pharmacology.
Company
Christopher Barbieri currently works at Bristol Myers Squibb as an Associate Director in New Jersey, United States. He has been with the company in various roles since 2017, including as Senior Principal Scientist from 2020 to 2022 and as Principal Scientist from 2017 to 2020. Before joining Bristol Myers Squibb, he was an Associate Principal Scientist at Merck in Kenilworth, NJ.
Title
Christopher Barbieri holds the position of Associate Director at Bristol Myers Squibb. His responsibilities include leading projects and teams, with a focus on advanced scientific research and drug development.
Education and Expertise
Christopher Barbieri earned his Ph.D. in Pharmacology from Rutgers Robert Wood Johnson Medical School from 2001 to 2006. Prior to that, he obtained a B.S. in Biochemistry from Rutgers University between 1995 and 1999. He is skilled in high-throughput screening and externalization for characterizing molecular interactions. He also specializes in a variety of biophysical techniques, including FRET, CD, calorimetry, ITC, DSC, and SPR.
Background
Christopher Barbieri's early career includes a postdoctoral research associate position at UMDNJ-Robert Wood Johnson Medical School, where he worked from 2007 to 2012. He also spent time as a graduate student at Rutgers University/University of Medicine and Dentistry of New Jersey from 2001 to 2006. His experience spans antimicrobial and cancer pharmacology, and he has a strong foundation in both protein and nucleic acid biochemistry.
Achievements
Christopher Barbieri has developed a comprehensive understanding of signal transduction mechanisms over his extensive career. He is adept in various spectroscopy methods and time-resolved fluorescence techniques, broadening his expertise in the biochemistry field. This diversified skill set has been integral to his roles in both academic and pharmaceutical research environments.